Literature DB >> 32799009

Multiple pathophysiological roles of midkine in human disease.

Ya-Qin Cai1, Yuncheng Lv1, Zhong-Cheng Mo1, Jiashun Lei2, Jing-Ling Zhu2, Qiao-Qing Zhong3.   

Abstract

Midkine (MK) is a low molecular-weight protein that was first identified as the product of a retinoic acid-responsive gene involved in embryonic development. Recent studies have indicated that MK levels are related to various diseases, including cardiovascular disease (CVD), renal disease and autoimmune disease. MK is a growth factor involved in multiple pathophysiological processes, such as inflammation, the repair of damaged tissues and cancer. The pathophysiological roles of MK are diverse. MK enhances the recruitment and migration of inflammatory cells upon inflammation directly and also through induction of chemokines, and contributes to tissue damage. In lung endothelial cells, oxidative stress increased the expression of MK, which induced angiotensin-converting enzyme (ACE) expression and the consequent conversion from Ang I to Ang II, leading to further oxidative stress. MK inhibited cholesterol efflux from macrophages by reducing ATP-binding cassette transporter A1 (ABCA1) expression, which is involved in lipid metabolism, suggesting that MK is an important positive factor involved in inflammation, oxidative stress and lipid metabolism. Furthermore, MK can regulate the expansion, differentiation and activation of T cells as well as B-cell survival; mediate angiogenic and antibacterial activity; and possess anti-apoptotic activity. In this paper, we summarize the pathophysiological roles of MK in human disease.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-apoptotic activity; Inflammation; Lipid metabolism; Midkine; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32799009     DOI: 10.1016/j.cyto.2020.155242

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Midkine promotes kidney injury in diabetic kidney disease by increasing neutrophil extracellular traps formation.

Authors:  Gaohong Liu; Xiaojun Ren; Yousong Li; Han Li
Journal:  Ann Transl Med       Date:  2022-06

2.  CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Authors:  Yves Lévy; Aurélie Wiedemann; Boris P Hejblum; Mélany Durand; Cécile Lefebvre; Mathieu Surénaud; Christine Lacabaratz; Matthieu Perreau; Emile Foucat; Marie Déchenaud; Pascaline Tisserand; Fabiola Blengio; Benjamin Hivert; Marine Gauthier; Minerva Cervantes-Gonzalez; Delphine Bachelet; Cédric Laouénan; Lila Bouadma; Jean-François Timsit; Yazdan Yazdanpanah; Giuseppe Pantaleo; Hakim Hocini; Rodolphe Thiébaut
Journal:  iScience       Date:  2021-06-10

Review 3.  Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics.

Authors:  Maria Maslyanko; Ryan D Harris; David Mu
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

4.  Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production.

Authors:  Elias A Said; Sumaya Al-Dughaishi; Wadha Al-Hatmi; Iman Al-Reesi; Marwa Al-Riyami; Mohammed S Al-Balushi; Atika Al-Bimani; Juma Z Al-Busaidi; Murtadha Al-Khabori; Salam Al-Kindi; Francesco A Procopio; Afrah Al-Rashdi; Aliyaa Al-Ansari; Hamza Babiker; Crystal Y Koh; Khalid Al-Naamani; Giuseppe Pantaleo; Ali A Al-Jabri
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

Review 5.  Midkine-A novel player in cardiovascular diseases.

Authors:  Marina Majaj; Ludwig T Weckbach
Journal:  Front Cardiovasc Med       Date:  2022-09-20

6.  Protease nexin-1 deficiency increases mouse hindlimb neovascularisation following ischemia and accelerates femoral artery perfusion.

Authors:  Sonia Selbonne; Celina Madjene; Benjamin Salmon; Yacine Boulaftali; Marie-Christine Bouton; Véronique Arocas
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.